Hikma Pharmaceutical | HIK - Cash And Equivalent



Hikma Pharmaceutical reported $188M in Cash and Equivalent for its fiscal semester ending in December of 2024.


Cash And Equivalent Change Date
Almirall EUR 374.4M 2.7M Mar/2025
argenx SE 2.09B 586.04M Jun/2025
AstraZeneca USD 7.06B 1.83B Jun/2025
Autolus Therapeutics Ltd 123.82M 28.02M Jun/2025
Bayer EUR 4.56B 542M Jun/2025
Fresenius EUR 1.23B 1.16B Jun/2025
Galapagos EUR 108.07M 43.83M Mar/2025
Genmab DKK 1.3B 323M Jun/2025
GlaxoSmithKline GBP 3.6B 865M Jun/2025
GRIFOLS EUR 558.69M 194.13M Jun/2025
Hikma Pharmaceutical USD 188M 188M Dec/2024
Lonza CHF 1.11B 286M Dec/2024
Merck EUR 1.17B 161M Jun/2025
Orion EUR 259.4M 53.8M Mar/2025
Recordati EUR 341.55M 8.51M Jun/2025
Roche Holding CHF 6.98B 2.15B Dec/2024
Sanofi 15.36B 7.37B Jun/2025
UCB EUR 1.57B 1.14B Dec/2024